KARYOPHARM THERAPEUTICS INC (KPTI:NASDAQ)

$9.51 0.13 (1.3859%)

watchlist-icon
search-icon
Profile Icon

Most Recent Average Sentiment Analysis Score (0 to 100): 69

negative-sentiment
Negative [0, 35)
neutral-sentiment
Neutral [35, 65]
positive-sentiment
Positive (65, 100]
Visualize Sentiment Trendline

Analysed KARYOPHARM THERAPEUTICS INC (KPTI:NASDAQ) News Sources

Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation

01-06-2026

yahoo.com

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

01-06-2026

yahoo.com

Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology

02-06-2026

yahoo.com

Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026

02-06-2026

yahoo.com

Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026

03-06-2026

yahoo.com

How The Investment Story Is Evolving For Karyopharm Therapeutics (KPTI)

07-06-2026

yahoo.com

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

14-06-2026

yahoo.com

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

14-06-2026

yahoo.com

Karyopharm Therapeutics (KPTI) Stock Sees Split Analyst Revisions After Phase 3 Trial Update

25-06-2026

yahoo.com

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01-07-2026

yahoo.com

KARYOPHARM THERAPEUTICS INC (KPTI:NASDAQ) Sentiment Trend

0 25 50 75 100 87 65 69 76 83 86 56 78 23 68 01-06-2026 02-06-2026 03-06-2026 07-06-2026 14-06-2026 25-06-2026 01-07-2026 #1 #2 #3 #4 #5 #6 #7 #8 #9 #10 Negative < 35 Neutral 35–65 Positive > 65 View FAQ

KARYOPHARM THERAPEUTICS INC (KPTI:NASDAQ) FAQs

toggle

What is the current price of KARYOPHARM THERAPEUTICS INC (KPTI:NASDAQ)?

The current price of KARYOPHARM THERAPEUTICS INC (KPTI:NASDAQ) is $9.51.


toggle

KARYOPHARM THERAPEUTICS INC (KPTI:NASDAQ) absolute price change since previous trading day?

The absolute price change of KARYOPHARM THERAPEUTICS INC (KPTI:NASDAQ) since the previous trading day is $0.13.


toggle

KARYOPHARM THERAPEUTICS INC (KPTI:NASDAQ) percentage price change since previous trading day?

The percentage price change of KARYOPHARM THERAPEUTICS INC (KPTI:NASDAQ) since the previous trading day is 1.3859%.


toggle

What is the most recent average sentiment score for KARYOPHARM THERAPEUTICS INC (KPTI:NASDAQ)?

The most recent average sentiment score for KARYOPHARM THERAPEUTICS INC (KPTI:NASDAQ) is 69 out of 100.


toggle

What is the most recent average sentiment for KARYOPHARM THERAPEUTICS INC (KPTI:NASDAQ)?

The most recent sentiment for KARYOPHARM THERAPEUTICS INC (KPTI:NASDAQ) is .


SEC-8K** Filing Available For KARYOPHARM THERAPEUTICS INC (KPTI:NASDAQ)

** material developments that could impact a company's financial condition or stock price.

Author: MattELab

X Icon

GitHub Icon

MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.